---
document_datetime: 2025-12-02 05:50:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/temozolomide-sun.html
document_name: temozolomide-sun.html
version: success
processing_time: 0.141342
conversion_datetime: 2025-12-25 01:26:27.729866
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Temozolomide Sun

[RSS](/en/individual-human-medicine.xml/65522)

##### Authorised

This medicine is authorised for use in the European Union

temozolomide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Product information - with tracked changes](#product-information-with-tracked-changes-77914)
- [More information on Temozolomide Sun](#more-information-on-temozolomide-sun-1000)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Temozolomide Sun. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Temozolomide Sun.

Expand section

Collapse section

## What is Temozolomide Sun?

Temozolomide Sun is a medicine that contains the active substance temozolomide. It is available as capsules (5, 20, 100, 140, 180 and 250 mg).

Temozolomide Sun is a 'generic medicine'. This means that Temozolomide Sun is similar to a 'reference medicine' already authorised in the European Union (EU) called Temodal.

## What is Temozolomide Sun used for?

Temozolomide Sun is an anticancer medicine. It is used to treat malignant glioma (brain tumours) in the following groups of patients:

- adults with newly diagnosed glioblastoma multiforme (an aggressive type of brain tumour). Temozolomide Sun is used first with radiotherapy and then on its own;
- adults and children three years of age and over with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, when the tumour has returned or got worse after standard treatment. Temozolomide Sun is used on its own in these patients.

The medicine can only be obtained with a prescription.

## How is Temozolomide Sun used?

Treatment with Temozolomide Sun should be prescribed by a doctor with experience in the treatment of brain tumours.

The dose of Temozolomide Sun depends on body surface area (calculated using the patient's height and weight) and ranges from 75 to 200 mg per square metre, once a day. The dose and the number of doses depend on the type of tumour being treated, whether the patient has been treated before, whether Temozolomide Sun is being used alone or with other treatments, and how the patient responds to treatment. Temozolomide Sun should be taken without food.

Patients may also need to take medicines to prevent vomiting before taking Temozolomide Sun. Temozolomide Sun should be used with caution in patients with severe liver problems or with kidney problems.

For full details, see the summary of product characteristics (also part of the EPAR).

## How does Temozolomide Sun work?

The active substance in Temozolomide Sun, temozolomide, belongs to a group of anticancer medicines called alkylating agents. In the body, temozolomide is converted to another compound called MTIC. MTIC binds to the DNA of cells while they are reproducing, which stops cell division. As a result, the cancer cells cannot divide, slowing down the growth of tumours.

## How has Temozolomide Sun been studied?

Because Temozolomide Sun is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Temodal. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Temozolomide Sun?

Because Temozolomide Sun is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why has Temozolomide Sun been approved?

The CHMP concluded that, in accordance with EU requirements, Temozolomide Sun has been shown to have comparable quality and to be bioequivalent to Temodal. Therefore, the CHMP's view was that, as for Temodal, the benefit outweighs the identified risk. The Committee recommended that Temozolomide Sun be given marketing authorisation.

## Other information about Temozolomide Sun

The European Commission granted a marketing authorisation valid throughout the European Union for Temozolomide Sun on 13 July 2011.

For more information about treatment with Temozolomide Sun, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Temozolomide Sun : EPAR - Summary for the public

English (EN) (67.61 KB - PDF)

**First published:** 02/08/2011

**Last updated:** 02/08/2011

[View](/en/documents/overview/temozolomide-sun-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-596)

български (BG) (166.99 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/bg/documents/overview/temozolomide-sun-epar-summary-public_bg.pdf)

español (ES) (151.57 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/es/documents/overview/temozolomide-sun-epar-summary-public_es.pdf)

čeština (CS) (157.24 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/cs/documents/overview/temozolomide-sun-epar-summary-public_cs.pdf)

dansk (DA) (128.32 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/da/documents/overview/temozolomide-sun-epar-summary-public_da.pdf)

Deutsch (DE) (131.57 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/de/documents/overview/temozolomide-sun-epar-summary-public_de.pdf)

eesti keel (ET) (128.41 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/et/documents/overview/temozolomide-sun-epar-summary-public_et.pdf)

ελληνικά (EL) (169.54 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/el/documents/overview/temozolomide-sun-epar-summary-public_el.pdf)

français (FR) (131.27 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/fr/documents/overview/temozolomide-sun-epar-summary-public_fr.pdf)

italiano (IT) (130.99 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/it/documents/overview/temozolomide-sun-epar-summary-public_it.pdf)

latviešu valoda (LV) (156.62 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/lv/documents/overview/temozolomide-sun-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (153.29 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/lt/documents/overview/temozolomide-sun-epar-summary-public_lt.pdf)

magyar (HU) (92.88 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/hu/documents/overview/temozolomide-sun-epar-summary-public_hu.pdf)

Malti (MT) (150.23 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/mt/documents/overview/temozolomide-sun-epar-summary-public_mt.pdf)

Nederlands (NL) (130.62 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/nl/documents/overview/temozolomide-sun-epar-summary-public_nl.pdf)

polski (PL) (157.7 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/pl/documents/overview/temozolomide-sun-epar-summary-public_pl.pdf)

português (PT) (130.92 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/pt/documents/overview/temozolomide-sun-epar-summary-public_pt.pdf)

română (RO) (93.89 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/ro/documents/overview/temozolomide-sun-epar-summary-public_ro.pdf)

slovenčina (SK) (154.39 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/sk/documents/overview/temozolomide-sun-epar-summary-public_sk.pdf)

slovenščina (SL) (91.42 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/sl/documents/overview/temozolomide-sun-epar-summary-public_sl.pdf)

Suomi (FI) (129.18 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/fi/documents/overview/temozolomide-sun-epar-summary-public_fi.pdf)

svenska (SV) (129.37 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

02/08/2011

[View](/sv/documents/overview/temozolomide-sun-epar-summary-public_sv.pdf)

## Product information

Temozolomide Sun : EPAR - Product Information

English (EN) (803.26 KB - PDF)

**First published:** 02/08/2011

**Last updated:** 10/07/2025

[View](/en/documents/product-information/temozolomide-sun-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-924)

български (BG) (1.13 MB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/bg/documents/product-information/temozolomide-sun-epar-product-information_bg.pdf)

español (ES) (872.23 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/es/documents/product-information/temozolomide-sun-epar-product-information_es.pdf)

čeština (CS) (980.32 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/cs/documents/product-information/temozolomide-sun-epar-product-information_cs.pdf)

dansk (DA) (669.35 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/da/documents/product-information/temozolomide-sun-epar-product-information_da.pdf)

Deutsch (DE) (977 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/de/documents/product-information/temozolomide-sun-epar-product-information_de.pdf)

eesti keel (ET) (872.49 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/et/documents/product-information/temozolomide-sun-epar-product-information_et.pdf)

ελληνικά (EL) (1.23 MB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/el/documents/product-information/temozolomide-sun-epar-product-information_el.pdf)

français (FR) (993.2 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/fr/documents/product-information/temozolomide-sun-epar-product-information_fr.pdf)

hrvatski (HR) (853.39 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/hr/documents/product-information/temozolomide-sun-epar-product-information_hr.pdf)

íslenska (IS) (882.08 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/is/documents/product-information/temozolomide-sun-epar-product-information_is.pdf)

italiano (IT) (909.69 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/it/documents/product-information/temozolomide-sun-epar-product-information_it.pdf)

latviešu valoda (LV) (967 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/lv/documents/product-information/temozolomide-sun-epar-product-information_lv.pdf)

lietuvių kalba (LT) (996.21 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/lt/documents/product-information/temozolomide-sun-epar-product-information_lt.pdf)

magyar (HU) (990.98 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/hu/documents/product-information/temozolomide-sun-epar-product-information_hu.pdf)

Malti (MT) (1002.12 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/mt/documents/product-information/temozolomide-sun-epar-product-information_mt.pdf)

Nederlands (NL) (943.07 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/nl/documents/product-information/temozolomide-sun-epar-product-information_nl.pdf)

norsk (NO) (841.53 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/no/documents/product-information/temozolomide-sun-epar-product-information_no.pdf)

polski (PL) (1.15 MB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/pl/documents/product-information/temozolomide-sun-epar-product-information_pl.pdf)

português (PT) (681.84 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/pt/documents/product-information/temozolomide-sun-epar-product-information_pt.pdf)

română (RO) (1.2 MB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/ro/documents/product-information/temozolomide-sun-epar-product-information_ro.pdf)

slovenčina (SK) (1.05 MB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/sk/documents/product-information/temozolomide-sun-epar-product-information_sk.pdf)

slovenščina (SL) (921.9 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/sl/documents/product-information/temozolomide-sun-epar-product-information_sl.pdf)

Suomi (FI) (865.94 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/fi/documents/product-information/temozolomide-sun-epar-product-information_fi.pdf)

svenska (SV) (925.83 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

10/07/2025

[View](/sv/documents/product-information/temozolomide-sun-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000271887 10/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Temozolomide Sun : EPAR - All Authorised presentations

English (EN) (19.84 KB - PDF)

**First published:** 02/08/2011

**Last updated:** 03/09/2018

[View](/en/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-109)

български (BG) (47.11 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/bg/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_bg.pdf)

español (ES) (16.86 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/es/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_es.pdf)

čeština (CS) (27.55 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/cs/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (18.32 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/da/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (18.71 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/de/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (19.08 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/et/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (45.41 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/el/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_el.pdf)

français (FR) (18.96 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/fr/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (30.54 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/hr/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (18.35 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/is/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.36 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/it/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (43.9 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/lv/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (43.86 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/lt/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (43.87 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/hu/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (42.67 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/mt/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (17.65 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/nl/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (18.25 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/no/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_no.pdf)

polski (PL) (44.99 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/pl/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_pl.pdf)

português (PT) (18.72 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/pt/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_pt.pdf)

română (RO) (42.77 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/ro/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (28.57 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/sk/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (20.05 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/sl/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (18.71 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/fi/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (18.67 KB - PDF)

**First published:**

02/08/2011

**Last updated:**

03/09/2018

[View](/sv/documents/all-authorised-presentations/temozolomide-sun-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Temozolomide Sun Active substance temozolomide International non-proprietary name (INN) or common name temozolomide Therapeutic area (MeSH) Glioma Anatomical therapeutic chemical (ATC) code L01AX03

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Temozolomide Sun is indicated for the treatment of:

- adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment;
- children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

## Authorisation details

EMA product number EMEA/H/C/002198

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Sun Pharmaceutical Industries Europe B.V.

Polarisavenue 87

Marketing authorisation issued 13/07/2011 Revision 21

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Temozolomide Sun : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (398.58 KB - PDF)

**First published:** 21/05/2024

**Last updated:** 10/07/2025

[View](/en/documents/procedural-steps-after/temozolomide-sun-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Temozolomide Sun : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (191 KB - PDF)

**First published:** 12/09/2012

**Last updated:** 21/05/2024

[View](/en/documents/procedural-steps-after/temozolomide-sun-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Temozolomide Sun : EPAR - Public assessment report

Adopted

Reference Number: EMA/555661/2011

English (EN) (303.6 KB - PDF)

**First published:** 02/08/2011

**Last updated:** 02/08/2011

[View](/en/documents/assessment-report/temozolomide-sun-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Temozolomide Sun

Adopted

Reference Number: EMA/CHMP/354114/2011

English (EN) (60.75 KB - PDF)

**First published:** 20/05/2011

**Last updated:** 20/05/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-temozolomide-sun_en.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Temozolomide Sun : EPAR - Product information - tracked changes

English (EN) (383.95 KB - DOCX)

**First published:** 10/07/2025

[View](/en/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-423)

български (BG) (473.93 KB - DOCX)

**First published:**

10/07/2025

[View](/bg/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_bg.docx)

español (ES) (625.5 KB - DOC)

**First published:**

10/07/2025

[View](/es/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_es.doc)

čeština (CS) (443.08 KB - DOCX)

**First published:**

10/07/2025

[View](/cs/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (453.04 KB - DOCX)

**First published:**

10/07/2025

[View](/da/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (457.13 KB - DOCX)

**First published:**

10/07/2025

[View](/de/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (650 KB - DOC)

**First published:**

10/07/2025

[View](/et/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_et.doc)

ελληνικά (EL) (703.5 KB - DOC)

**First published:**

10/07/2025

[View](/el/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_el.doc)

français (FR) (898.5 KB - DOC)

**First published:**

10/07/2025

[View](/fr/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_fr.doc)

hrvatski (HR) (682.5 KB - DOC)

**First published:**

10/07/2025

[View](/hr/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_hr.doc)

íslenska (IS) (2.13 MB - DOC)

**First published:**

10/07/2025

[View](/is/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_is.doc)

italiano (IT) (605.5 KB - DOC)

**First published:**

10/07/2025

[View](/it/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_it.doc)

latviešu valoda (LV) (680 KB - DOC)

**First published:**

10/07/2025

[View](/lv/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_lv.doc)

lietuvių kalba (LT) (694.5 KB - DOC)

**First published:**

10/07/2025

[View](/lt/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_lt.doc)

magyar (HU) (740 KB - DOC)

**First published:**

10/07/2025

[View](/hu/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_hu.doc)

Malti (MT) (726 KB - DOC)

**First published:**

10/07/2025

[View](/mt/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_mt.doc)

Nederlands (NL) (653 KB - DOC)

**First published:**

10/07/2025

[View](/nl/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_nl.doc)

norsk (NO) (639.5 KB - DOC)

**First published:**

10/07/2025

[View](/no/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_no.doc)

polski (PL) (763 KB - DOC)

**First published:**

10/07/2025

[View](/pl/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_pl.doc)

português (PT) (627.5 KB - DOC)

**First published:**

10/07/2025

[View](/pt/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_pt.doc)

română (RO) (725 KB - DOC)

**First published:**

10/07/2025

[View](/ro/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_ro.doc)

slovenčina (SK) (462.14 KB - DOCX)

**First published:**

10/07/2025

[View](/sk/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (447.99 KB - DOCX)

**First published:**

10/07/2025

[View](/sl/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (633.5 KB - DOC)

**First published:**

10/07/2025

[View](/fi/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_fi.doc)

svenska (SV) (469.55 KB - DOCX)

**First published:**

10/07/2025

[View](/sv/documents/product-information-tracked-changes/temozolomide-sun-epar-product-information-tracked-changes_sv.docx)

#### More information on Temozolomide Sun

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 10/07/2025

## Share this page

[Back to top](#main-content)